Identification of Neurocognitive Disorders by General Practitioners in Primary Care — TROCOMEGE  

Neurocognitive Disorders Clinical Trial

Official title: Identification of Neurocognitive Disorders by General Practitioners in Primary Care

Status Recruiting

Clinical Trial Summary

Neurocognitive disorders (NCD) are today often largely underdiagnosed or diagnosed in late stages in France. Indeed the ALzheimer COoperative Valuation in Europe (ALCOVE) study stated that about 50% of people living with NCD remain undiagnosed until late severe stages with a deep autonomy loss inducing at risk behaviours and/or behavioural crisis. The French High Authority of Health (Haute Autorité de Santé - HAS) and ALCOVE recommend a timely diagnosis at a time when the specific intervention help to implement secondary or tertiary prevention dynamics that would delay severe complications and help to maintain a reasonable quality of life for both the patient and the caregiver. Moreover, the representatives of the National College of General Practitioners, the French Federation of Memory Centres, the French Federation of Gerontology and Geriatrics, the French Federation of Neurology, the French Society of Psychogeriatrics and the National Plan on Neurodegenerative Diseases designed a hierarchized and tailored diagnosis strategy of NCD promoting a shared diagnosis between the General Practitioner (GP) and specialists of NCD. It therefore appears crucial to determine the diagnosis value of a short duration strategy assessing the complaint, cognition and autonomy in primary care to detect NCD and referring to a specialist to perform the etiological diagnosis. The identification of NCD by GP in primary care (TROCOMEGE) study aims at assessing the positive and negative predictive values of a NCD diagnosis strategy through the assessment of the subjective memory complaint, the cognitive status and the autonomy level in primary care. It relies on the clinical impression of the GP, a cognitive complaint interview for complaint and functional assessment thanks to the General Practitioner assessment of Cognition (GP-Cog, part 2) tool and the cognitive assessment thanks to the Six-Item Cognitive Impairment test (6-CIT).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Neurocognitive Disorders

• NCT number: NCT03678376
• Study type: Interventional
• Source: Hospices Civils de Lyon
• Contact: Pierre Krolak Salmon, Pr
• Phone: 4 72 43 20 50
• Email: pierre.krolak-salmon@chu-lyon.fr
• Status: Recruiting
• Phase: N/A
• Start date: February 17, 2020
• Completion date: August 17, 2024